Huntsman Cancer Institute (HCI) seeks to establish itself as a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS) to provide leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. HCI is the only academic medical center and the only NCI-Designated Cancer Center in the Intermountain West, drawing clinical trials patients from across Utah as well as from Idaho, Nevada, and Wyoming, where no academic medical centers exist The HCI NLAPS will provide scientific leadership in development and conduct of clinical trials in association with SWOG, NRG, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS leadership team is well-qualified and experienced in cooperative group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and participation in RTOG and GOG. HCI has a vigorous and growing clinical trials program, with strong commitment from the University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and a centralized single-point-of-service infrastructure for the clinical research enterprise. Our Center also has unique assets that are valuable for clinical research efforts, including rural and Native American populations, an NCI Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful research linkage of population-based genealogical data and statewide medical records. HCI has a strong, established commitment to participation in cooperative group clinical trials: 35% of HCI therapeutic accruals are annually made to NCTN trials and, consistently, >50 NCTN therapeutic trials are open. HCI's participation in NCTN research has grown: in 2007, 95 patients were enrolled on therapeutic NCTN trials; in 2012, HCI will reach >150 therapeutic NCTN enrollments. In 2011, HCI was the second leading site for SWOG accruals overall and the sixth leading site for the three cooperative groups merging to form NRG. HCI would be a strong partner to the NCTN program through its efforts as a Cancer Center characterized by expertise, leadership, and active accrual.
Huntsman Cancer Institute (HCI) will provide leadership in the development, conduct, and oversight of NCTN cooperative clinical trials, comprehensive support for the network, robust accruals to a broad array of trials, including trials in rare cances, and unique assets that can contribute value to the NCTN Program. HCI will work vigorously to ensure the success of the NCTN's cooperative endeavors to eradicate cancer.
|Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641|
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2017) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol :JCO2017746651|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Li, X Allen; Chen, Xiaojian; Zhang, Qiang et al. (2016) Margin reduction from image guided radiation therapy for soft tissue sarcoma: Secondary analysis of Radiation Therapy Oncology Group 0630 results. Pract Radiat Oncol 6:e135-40|
|Golshan, Mehra; Cirrincione, Constance T; Sikov, William M et al. (2016) Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat 160:297-304|
|Rogers, C Leland; Perry, Arie; Pugh, Stephanie et al. (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18:565-74|
Showing the most recent 10 out of 28 publications